Zealand Pharma Surprises with Smaller Loss and Bold $200M Share Buyback

Zealand Pharma exceeded market expectations in Q1 with a reduced operating loss, citing robust obesity drug pipeline progress. The company announced a $200 million share buyback and confirmed its future funding strength, partly due to an anticipated $700 million from Roche by 2026.

Danish pharmaceutical company Zealand Pharma reported a less-than-expected operating loss for the first quarter of the year, driven by strong developments in its obesity drug pipeline. The firm also announced a share buyback program of up to $200 million, signaling a confident future outlook.

The company's operating loss was recorded at 539 million Danish crowns, surpassing analysts' projections of a higher loss of 672.4 million crowns. Zealand Pharma’s cash holdings ended at 14.47 billion crowns at March's end, slightly down from the previous year's closure.

CEO Adam Steensberg emphasized the quarter's advancements have fortified the company’s long-term goals. Looking ahead, Zealand foresees a significant influx of $700 million from a partnership with Roche, which includes the progress of their experimental obesity drug, petrelintide, into Phase 3 trials.